Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,231.10 | 2.60 | 0.03% |
CAC 40 | 7,749.73 | 39.92 | 0.52% |
DAX 40 | 24,072.74 | 80.13 | -0.33% |
Dow JONES (US) | 45,449.88 | 31.81 | 0.07% |
FTSE 100 | 9,249.50 | 16.30 | -0.18% |
HKSE | 25,201.76 | 323.16 | -1.27% |
NASDAQ | 21,510.15 | 34.12 | -0.16% |
Nikkei 225 | 42,520.27 | 125.87 | 0.30% |
NZX 50 Index | 12,861.84 | 96.14 | -0.74% |
S&P 500 | 6,462.95 | 2.99 | -0.05% |
S&P/ASX 200 | 8,960.50 | 0.70 | -0.01% |
SSE Composite Index | 3,800.35 | 68.03 | -1.76% |